{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:42:10Z","timestamp":1781739730526,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2457-0","type":"journal-article","created":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T04:17:54Z","timestamp":1467865074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed"],"prefix":"10.1186","volume":"16","author":[{"given":"Sojung","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang\u2013Min","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang\u2013We","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung\u2013Shin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hoon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Kyung","family":"Rho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5963-0259","authenticated-orcid":false,"given":"Jae Cheol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,7]]},"reference":[{"key":"2457_CR1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4143\/crt.2013.45.3.162","volume":"45","author":"KW Jung","year":"2013","unstructured":"Jung KW, Won YJ, Kong HJ, Oh CM, As S, Lee JS. Survival of Korean Adult Cancer Patients by Stage at Diagnosis, 2006-2010: National Cancer Registry Study. Cancer Res Treat. 2013;45:162\u201371.","journal-title":"Cancer Res Treat"},{"key":"2457_CR2","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","volume":"26","author":"GV Scagliotti","year":"2008","unstructured":"Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543\u201351.","journal-title":"J Clin Oncol"},{"key":"2457_CR3","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","volume":"22","author":"N Hanna","year":"2004","unstructured":"Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589\u201397.","journal-title":"J Clin Oncol"},{"key":"2457_CR4","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.2008.20.9114","volume":"27","author":"BH Gr\u00f8nberg","year":"2009","unstructured":"Gr\u00f8nberg BH, Bremnes RM, Fl\u00f8tten O, Amundsen T, Brunsvig PF, Hjelde HH, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27:3217\u201324.","journal-title":"J Clin Oncol"},{"key":"2457_CR5","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/j.cllc.2015.01.003","volume":"16","author":"S Park","year":"2015","unstructured":"Park S, Park TS, Choi CM, Lee DH, Kim SW, Lee JS, et al. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements. Clin Lung Cancer. 2015;16:e83\u20139.","journal-title":"Clin Lung Cancer"},{"key":"2457_CR6","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. New Engl J Med. 2014;371:2167\u201377.","journal-title":"New Engl J Med"},{"key":"2457_CR7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/annonc\/mds242","volume":"24","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Varghese AM, Solomon BJ, Costa DB, Novello S, Mino-Kenudson M, et al. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Ann Oncol. 2013;24:59\u201366.","journal-title":"Ann Oncol"},{"key":"2457_CR8","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1097\/JTO.0b013e3182208ea8","volume":"6","author":"JM Sun","year":"2011","unstructured":"Sun JM, Han J, Ahn JS, Park K, Ahn MJ. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol. 2011;6:1392\u20139.","journal-title":"J Thorac Oncol"},{"key":"2457_CR9","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1097\/JTO.0b013e3182a406a3","volume":"8","author":"BH Gr\u00f8nberg","year":"2013","unstructured":"Gr\u00f8nberg BH, Lund-Iversen M, Str\u00f8m EH, Brustugun OT, Scott H. Associations between TS, TTF-1, FR-\u03b1, FPGS, and overall survival in patients with advanced non\u2013small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy. J Thorac Oncol. 2013;8:1255\u201364.","journal-title":"J Thorac Oncol"},{"key":"2457_CR10","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.3892\/ol.2014.1988","volume":"7","author":"W Mou","year":"2014","unstructured":"Mou W, Xue H, Tong H, Sun S, Zhang Z, Zhang C, et al. Prognostic value of serum leptin in advanced lung adenocarcinoma patients with cisplatin\/pemetrexed chemotherapy. Oncol Lett. 2014;7:2073\u20138.","journal-title":"Oncol Lett"},{"key":"2457_CR11","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.2012.48.1911","volume":"31","author":"M Zukin","year":"2013","unstructured":"Zukin M, Barrios CH, Pereira JR, Ribeiro Rde A, Beato CA, Do Nascimento YN, et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol. 2013;31:2849\u201353.","journal-title":"J Clin Oncol"},{"key":"2457_CR12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"2457_CR13","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/jcmm.12278","volume":"18","author":"L Paz-Ares","year":"2014","unstructured":"Paz-Ares L, Soulieres D, Moecks J, Bara I, Mok T, Klughammer B. Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC. J Cell Mol Med. 2014;18:1519\u201339.","journal-title":"J Cell Mol Med"},{"key":"2457_CR14","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/JTO.0b013e31820cf053","volume":"6","author":"DR Camidge","year":"2011","unstructured":"Camidge DR, Kono SA, Lu X, Okuyama S, Baron AE, Oton AB, et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol. 2011;6:774\u201380.","journal-title":"J Thorac Oncol"},{"key":"2457_CR15","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1097\/JTO.0b013e3182208fc2","volume":"6","author":"JO Lee","year":"2011","unstructured":"Lee JO, Kim TM, Lee SH, Kim DW, Kim S, Jeon YK, et al. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol. 2011;6:1474\u201380.","journal-title":"J Thorac Oncol"},{"key":"2457_CR16","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385\u201394.","journal-title":"N Engl J Med"},{"key":"2457_CR17","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.lungcan.2014.02.006","volume":"84","author":"J Sanchez De Cos Escuin","year":"2014","unstructured":"Sanchez De Cos Escuin J, Abal Arca J, Melchor Iniguez R, Miravel Sorribes L, Nunez Ares A, Hernandez Hemandez JR, et al. Tumor, node and metastasis classification of lung cancer--M1a versus M1b--analysis of M descriptors and other prognostic factors. Lung Cancer. 2014;84:182\u20139.","journal-title":"Lung Cancer"},{"key":"2457_CR18","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1002\/1097-0142(19900601)65:11<2426::AID-CNCR2820651104>3.0.CO;2-3","volume":"65","author":"RA Joss","year":"1990","unstructured":"Joss RA, Burki K, Dalquen P, Schatzmann E, Leyvraz S, Cavalli F, et al. Combination chemotherapy with mitomycin, vindesine, and cisplatin for non-small cell lung cancer. Association of antitumor activity with initial tumor burden and treatment center. Cancer. 1990;65:2426\u201334.","journal-title":"Cancer"},{"key":"2457_CR19","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1002\/cncr.24333","volume":"115","author":"Y Oh","year":"2009","unstructured":"Oh Y, Taylor S, Bekele BN, Debnam JM, Allen PK, Suki D, et al. Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases. Cancer. 2009;115:2930\u20138.","journal-title":"Cancer"},{"key":"2457_CR20","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cllc.2012.10.007","volume":"14","author":"JH Park","year":"2013","unstructured":"Park JH, Kim TM, Keam B, Jeon YK, Lee SH, Kim DW, et al. Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib. Clin Lung Cancer. 2013;14:383\u20139.","journal-title":"Clin Lung Cancer"},{"key":"2457_CR21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2014.11.017","volume":"87","author":"M Zhao","year":"2015","unstructured":"Zhao M, Zhang Y, Zhang H, Wang S, Zhang M, Chen X, et al. Hypoxia-induced cell stemness leads to drug resistance and poor prognosis in lung adenocarcinoma. Lung Cancer. 2015;87:98\u2013106.","journal-title":"Lung Cancer"},{"key":"2457_CR22","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10585-014-9648-3","volume":"31","author":"D Fujimoto","year":"2014","unstructured":"Fujimoto D, Ueda H, Shimizu R, Kato R, Otoshi T, Kawamura T, et al. Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis. Clin Exp Metastasis. 2014;31:543\u201351.","journal-title":"Clin Exp Metastasis"},{"key":"2457_CR23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","volume":"86","author":"M Riihim\u00e4ki","year":"2014","unstructured":"Riihim\u00e4ki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86:78\u201384.","journal-title":"Lung Cancer"},{"key":"2457_CR24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.lungcan.2015.02.012","volume":"88","author":"KL Wu","year":"2015","unstructured":"Wu KL, Tsai MJ, Yang CJ, Chang WA, Hung JY, Yen CJ, et al. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib. Lung Cancer. 2015;88:187\u201394.","journal-title":"Lung Cancer"},{"key":"2457_CR25","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/1097-0142(20010601)91:11<2033::AID-CNCR1229>3.0.CO;2-J","volume":"91","author":"C Louvet","year":"2001","unstructured":"Louvet C, de Gramont A, Tournigand C, Artru P, Maindrault\u2010Goebel F, Krulik M. Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer. 2001;91:2033\u20138.","journal-title":"Cancer"},{"key":"2457_CR26","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S1470-2045(06)70800-2","volume":"7","author":"KR Johnson","year":"2006","unstructured":"Johnson KR, Ringland C, Stokes BJ, Anthony DM, Freemantle N, Irs A, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol. 2006;7:741\u20136.","journal-title":"Lancet Oncol"},{"key":"2457_CR27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.lungcan.2009.07.013","volume":"68","author":"JM Sun","year":"2010","unstructured":"Sun JM, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, et al. The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer. Lung Cancer. 2010;68:427\u201332.","journal-title":"Lung Cancer"},{"key":"2457_CR28","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s12253-015-9955-2","volume":"21","author":"N Bittner","year":"2015","unstructured":"Bittner N, Baliko Z, Sarosi V, Laszlo T, Toth E, Kasler M, et al. Bone Metastases and the EGFR and KRAS Mutation Status in Lung Adenocarcinoma - The Results of Three Year Retrospective Analysis. Pathol Oncol Res. 2015;21:1217\u201321.","journal-title":"Pathol Oncol Res"},{"key":"2457_CR29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/JTO.0b013e31816de2b8","volume":"3","author":"JP Sculier","year":"2008","unstructured":"Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol. 2008;3:457\u201366.","journal-title":"J Thorac Oncol"},{"key":"2457_CR30","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/JTO.0b013e3181d2dcd9","volume":"5","author":"T Kawaguchi","year":"2010","unstructured":"Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol. 2010;5:620\u201330.","journal-title":"J Thorac Oncol"},{"key":"2457_CR31","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1200\/JCO.1991.9.9.1618","volume":"9","author":"KS Albain","year":"1991","unstructured":"Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991;9:1618\u201326.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2457-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T16:42:07Z","timestamp":1568133727000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2457-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,7]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2457"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2457-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,7]]},"article-number":"417"}}